Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Toxicity profile of bosutinib in pediatric patients with R/R CML

Erica Brivio, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, comments on the toxicity profile of tyrosine kinase inhibitors (TKIs) in pediatric patients with chronic myeloid leukemia (CML), focusing on bosutinib. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.